Overview
Primary brain tumors account for approximately 2% of all cancers but remain among the most challenging malignancies to treat. Despite advances in neuro-oncology, survival outcomes have improved more slowly compared to many other cancer types.
The two major categories of primary brain tumors are:
- Gliomas (including glioblastoma, astrocytoma, oligodendroglioma)
- Non-glioma tumors (including meningiomas, CNS embryonal tumors, and others)
Prognosis depends strongly on histology, molecular profile, and tumor grade.
Importance of Specialized Care
Brain tumor management requires a highly specialized, multidisciplinary approach due to the complexity of neuroanatomy, tumor heterogeneity, and evolving molecular classification.
In Germany, optimal care is delivered through personalized, molecularly guided treatment strategies, which represent the foundation of modern neuro-oncology and INDID Telemedicine workflows.
Accurate histopathological diagnosis, molecular profiling (e.g., IDH mutation, MGMT methylation), and precise imaging-based staging are essential for treatment planning.
Within INDID Telemedicine, cases are jointly coordinated with local physicians and reviewed in multidisciplinary neuro-oncology tumor boards at certified partner centers in Germany. Diagnostic inconsistencies or incomplete reports are actively identified and resolved through expert review.
Initial Diagnostic Workup and Staging
For most international patients, diagnostic workup and staging can be completed locally in coordination with INDID Telemedicine, without the need for immediate travel to Germany.
Baseline clinical assessment
- Medical and family history
- Full neurological examination (vision, hearing, coordination, strength, reflexes)
- Blood tests: full blood count, liver and renal function
Imaging
- MRI brain (gold standard for diagnosis and staging)
- Includes advanced sequences:
-Functional MRI (fMRI)
-Perfusion MRI
-MR spectroscopy
- CT brain (when MRI is not available or for emergency evaluation)
- PET-CT (selected cases for systemic evaluation or recurrence assessment)
High-quality DICOM imaging is essential. INDID Telemedicine coordinates repeat imaging when quality or completeness is insufficient for accurate diagnosis or staging.
Advanced MRI techniques (perfusion, diffusion, spectroscopy) are particularly important for tumor characterization, treatment planning, and differentiation of tumor progression versus treatment-related changes.
Pathology and Molecular Diagnostics
- Diagnostic confirmation requires stereotactic or image-guided biopsy
- Neuropathological evaluation determines:
- Tumor type (benign vs malignant)
- Primary vs metastatic origin
- Molecular markers (e.g., IDH mutation, MGMT promoter methylation)
Existing pathology reports are centrally reviewed. If required, tissue blocks (paraffin-embedded or frozen samples) may be reassessed in German reference neuropathology laboratories.
Liquid biopsy (ctDNA) may be considered in selected cases for monitoring and molecular characterization.
Systemic Staging
- CT thorax and abdomen with contrast to rule out extracranial metastases
- Whole-body MRI or PET-CT may be used in selected cases when clinically indicated
These advanced imaging modalities are highly informative but may be limited by availability or cost in some regions.
Multidisciplinary Treatment Planning
All cases are reviewed in neuro-oncology multidisciplinary tumor boards at partner centers in Germany.
Treatment decisions are based on:
- Histological tumor type
- WHO grade
- Molecular profile (IDH, MGMT, etc.)
- Tumor location and resectability
- Patient age and neurological status
Treatment Modalities
Surgery
Surgical resection is the primary therapeutic approach when feasible.
Goals include:
- Maximal safe resection
- Preservation of neurological function
- Reduction of tumor burden for adjuvant therapy
Even partial resection may provide clinical benefit in selected cases.
Radiotherapy
Radiotherapy is a cornerstone of brain tumor treatment and is often combined with surgery and/or chemotherapy.
- Conventional fractionated radiotherapy
- Stereotactic radiosurgery (SRS) for selected lesions
- Whole-brain radiotherapy for multifocal disease
Proton therapy may be considered in selected patients to reduce toxicity to surrounding brain structures.
Chemotherapy
Chemotherapy is commonly used depending on tumor type and molecular profile.
- Temozolomide is standard in glioblastoma and high-grade gliomas
- Other agents are selected based on histology and molecular markers
Therapy response is strongly influenced by molecular features such as MGMT promoter methylation.
Targeted and Molecular Therapy
Targeted therapies are increasingly used in molecularly defined brain tumors, including:
- IDH-targeted approaches (investigational/approved depending on region)
- BRAF/MEK pathway inhibitors (in selected tumors)
- Emerging precision oncology strategies based on molecular profiling
Supportive and Rehabilitative Care
Post-treatment recovery often includes:
- Physiotherapy
- Occupational therapy
- Speech and cognitive rehabilitation
These interventions are essential for neurological recovery and quality of life improvement.
Follow-Up Strategy
Follow-up is essential due to risk of recurrence and treatment-related changes.
Standard follow-up schedule
- Early follow-up: 2–3 months after treatment
- Then every 3–6 months for the first 2 years
- MRI brain as primary surveillance tool
- Additional imaging (MR spectroscopy, perfusion MRI, CT, PET) when indicated
PET imaging is used selectively, mainly in cases of suspected extracranial disease or diagnostic uncertainty.
Follow-up frequency is individualized based on tumor type, molecular profile, and clinical stability.
Telemedicine Follow-Up (INDID)
Patients treated in Germany typically do not require routine travel for follow-up.
INDID Telemedicine provides:
- Remote MRI review
- Neuro-oncology expert reassessment
- Long-term surveillance coordination
- Communication with local physicians
Key Strength of INDID Telemedicine Approach
INDID Telemedicine integrates:
- Cross-border completion of neuro-oncological diagnostics
- Centralized neuropathology and molecular review
- Multidisciplinary tumor board decision-making in Germany
- Personalized multimodal treatment planning
- Structured long-term remote follow-up and recurrence monitoring
This model ensures rapid access to German neuro-oncology expertise while reducing delays in diagnosis and minimizing unnecessary international travel.
References
- ASCO-SNO-ASTRO & EANO-ESMO (2026). Interdisciplinary clinical practice guidelines for the management of brain tumors. Annals of Oncology, 37(4), 410–428. https://doi.org/10.1016/j.annonc.2026.01.008
- Le Rhun, E., Preusser, M., van den Bent, M., et al. (2021). ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up of adult glioma. Annals of Oncology, 32(11), 1335–1360. https://doi.org/10.1016/j.annonc.2021.08.1746
Wamelink, I. J. H. G., Azizova, A., Booth, T. C., et al. (2024). Brain tumor imaging without gadolinium-based contrast agents: Feasible or fantasy? Radiology, 310. https://doi.org/10.1148/radiol.230793
